Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
decrease release » increased release (Expand Search)
significantly i » significantly _ (Expand Search), significantly high (Expand Search), significantly less (Expand Search)
i decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
decrease release » increased release (Expand Search)
significantly i » significantly _ (Expand Search), significantly high (Expand Search), significantly less (Expand Search)
i decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
-
21
Lack of Brain Insulin Receptor Substrate-1 Causes Growth Retardation, with Decreased Expression of Growth Hormone-Releasing Hormone in the Hypothalamus
Published 2021“…Although the ability of the pituitary to secrete growth hormone (GH) remained intact, the amount of hypothalamic growth hormone-releasing hormone (GHRH) was significantly decreased and accordingly, the pituitary GH mRNA expression levels were impaired in these mice. …”
-
22
The kinetic release data of the optimized formula compared to drug suspension.
Published 2025Subjects: -
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
33
-
34
-
35
-
36
Increasing TPP side chain length decreases melanoma cell viability and clonogenic survival.
Published 2020“…<p>(A) A375 and (B) MeWo melanoma cells were treated with 0.5 μM 5-, 8-, 10-, 12-,14-, or 16-TPP for 24 h, 48 h, or 72 h and analyzed for cell viability by the MTT method (* significant relative to control; p<0.05; N = 4). A375 melanoma cells were treated with 0.25 μM, 0.5 μM, or 1.0 μM 5-, 8-, 10-, 12-,14-, or 16-TPP for (C) 24 h and (D) 48 h and analyzed for clonogenic survival (* represents when 12-, 14-, and 16-TPP were significant relative to 5-TPP and 8-TPP; Ψ represents when 10-TPP was significant relative to 5-TPP and 8-TPP; p < 0.05; n = 3 from 2 separate experiments; N = 6). …”
-
37
-
38
-
39
-
40